Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine. Ford JH, Kurth T, Starling AJ, Ayer DW, et al. Headache 2020;60:2304-2319.

Read + Share

Amedeo Smart

Independent Medical Education